Research statistics

Anamorelin research: publications and trials

What has been published on Anamorelin: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Anamorelin works or is safe. For what it is and what the studies found, see the Anamorelin profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

146

Since 2007

Publications in 2026 so far

18

Through November 15, 2026

Human clinical research

47.3%

69 of 146 classified

Registered clinical trials

14

ClinicalTrials.gov

Randomized controlled trials

16

Publications reporting an RCT in people

Systematic reviews and meta-analyses

7

Preclinical studies

15.8%

13 animal · 9 in vitro · 1 computational

Records that only mention it

32

Not counted above

Status in the library: In clinical trials. Groups: Growth hormone axis.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.
  • Not a peptide: it is shown for completeness and left out of every peptide total.

Publications by year

Anamorelin publications by year and evidence

2007, Human clinical research: 1 of 12009, Human clinical research: 1 of 12011, Preclinical (animal, in vitro, computational): 1 of 12012, Human clinical research: 1 of 12013, Preclinical (animal, in vitro, computational): 1 of 12014, Human clinical research: 2 of 52014, Preclinical (animal, in vitro, computational): 1 of 52014, Reviews and meta-analyses: 1 of 52014, Other and not yet classified: 1 of 52015, Human clinical research: 1 of 62015, Preclinical (animal, in vitro, computational): 1 of 62015, Reviews and meta-analyses: 3 of 62015, Other and not yet classified: 1 of 62016, Human clinical research: 2 of 42016, Reviews and meta-analyses: 2 of 42017, Human clinical research: 3 of 122017, Reviews and meta-analyses: 7 of 122017, Other and not yet classified: 2 of 122018, Reviews and meta-analyses: 7 of 72019, Human clinical research: 2 of 42019, Reviews and meta-analyses: 2 of 42020, Preclinical (animal, in vitro, computational): 3 of 62020, Reviews and meta-analyses: 1 of 62020, Other and not yet classified: 2 of 62021, Human clinical research: 1 of 62021, Reviews and meta-analyses: 5 of 62022, Human clinical research: 7 of 112022, Preclinical (animal, in vitro, computational): 2 of 112022, Reviews and meta-analyses: 1 of 112022, Other and not yet classified: 1 of 112023, Human clinical research: 4 of 132023, Preclinical (animal, in vitro, computational): 2 of 132023, Reviews and meta-analyses: 4 of 132023, Other and not yet classified: 3 of 132024, Human clinical research: 16 of 272024, Preclinical (animal, in vitro, computational): 5 of 272024, Reviews and meta-analyses: 4 of 272024, Other and not yet classified: 2 of 272025, Human clinical research: 15 of 222025, Preclinical (animal, in vitro, computational): 3 of 222025, Reviews and meta-analyses: 3 of 222025, Other and not yet classified: 1 of 222026 (to date), Human clinical research: 13 of 182026 (to date), Preclinical (animal, in vitro, computational): 4 of 182026 (to date), Other and not yet classified: 1 of 18Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified010203020072013201720212026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
200710001
200910001
201101001
201210001
201301001
201421115
201511316
201620204
2017307212
201800707
201920204
202003126
202110506
2022721111
2023424313
20241654227
20251533122
2026 (to date)1340118

Study types

Observational human study37
Review33
Randomized controlled trial16
Editorial, letter or other14
Animal study13
Case report10
In vitro study9
Other clinical trial6
Meta-analysis5
Systematic review2
Computational study1

Research areas

From MeSH major topics. A paper can be in several areas.

Oncology109
Obesity and weight management90
Gastrointestinal25
Endocrinology18
Metabolic health18
Musculoskeletal8
Cardiovascular7
Neurological and mental health7
Immune system3
Cognitive health1

Registered clinical trials

2 of 10 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 10 · Active, not recruiting: 2 · Terminated: 2
Phase 1: 1 · Phase 2: 7 · Phase 2 / Phase 3: 1 · Phase 3: 5

TrialStatusPhaseStartedResults
Anamorelin Study for Advanced Pancreatic CancerNCT04844970 · 4 enrolledTerminatedPhase 22023-04Posted
Effect of a Ghrelin Receptor Agonist on Muscle and BoneNCT04021706 · 32 enrolledCompletedPhase 12019-12Posted
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 2NCT03743064 · 318 enrolledCompletedPhase 32019-05Posted
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1NCT03743051 · 318 enrolledCompletedPhase 32019-03Posted
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung CancerNCT03637816 · 25 enrolledActive, not recruitingPhase 2, Phase 32018-11—
Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid TumorsNCT03035409 · 129 enrolledActive, not recruitingPhase 22017-02Posted
The Role of Ghrelin in Cancer CachexiaNCT01505764 · 10 enrolledTerminatedPhase 22012-06Posted
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)NCT01387269 · 484 enrolledCompletedPhase 32011-07Posted
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)NCT01387282 · 495 enrolledCompletedPhase 32011-07Posted
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)NCT01395914 · 513 enrolledCompletedPhase 32011-07Posted
Dose Range Study of Anamorelin in Patients With Non-small Cell Lung CancerNCT00622193 · 228 enrolledCompletedPhase 22008-03—
Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/CachexiaNCT00378131 · 51 enrolledCompletedPhase 22006-09—
Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.NCT00267358CompletedPhase 22005-11—
Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight LossNCT00219817 · 80 enrolledCompletedPhase 22005-06—

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. The efficacy and safety of anamorelin for patients with cancer-related anorexia/cachexia syndrome: a systematic review and meta-analysis.

    Scientific reports · September 14, 2023 · Meta-analysis · cited 34 times · open access

    PMID 37709824 · DOI 10.1038/s41598-023-42446-x · Reviews and meta-analyses

  2. The effect of anamorelin (ONO-7643) on cachexia in cancer patients: Systematic review and meta-analysis of randomized controlled trials.

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · August 1, 2023 · Meta-analysis · cited 12 times

    PMID 37525932 · DOI 10.1177/10781552231189864 · Reviews and meta-analyses

  3. The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews.

    BMC complementary and alternative medicine · August 9, 2018 · Meta-analysis · cited 42 times · open access

    PMID 30092794 · DOI 10.1186/s12906-018-2304-8 · Reviews and meta-analyses

  4. Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis.

    Lung cancer (Amsterdam, Netherlands) · July 27, 2017 · Meta-analysis · cited 52 times

    PMID 29191597 · DOI 10.1016/j.lungcan.2017.07.023 · Reviews and meta-analyses

  5. Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · January 10, 2017 · Meta-analysis · cited 52 times

    PMID 28074289 · DOI 10.1007/s00520-016-3560-0 · Reviews and meta-analyses

  6. Efficacy and safety of pharmacotherapy for cancer cachexia: A systematic review and network meta-analysis.

    Cancer medicine · September 1, 2024 · Systematic review · cited 15 times · open access

    PMID 39225556 · DOI 10.1002/cam4.70166 · Reviews and meta-analyses

  7. Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials.

    BMC cancer · November 27, 2018 · Systematic review · cited 118 times · open access

    PMID 30482179 · DOI 10.1186/s12885-018-5080-4 · Reviews and meta-analyses

  8. Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.

    EClinicalMedicine · September 22, 2025 · Randomized controlled trial · cited 5 times · open access

    PMID 41181834 · DOI 10.1016/j.eclinm.2025.103500 · Human clinical research

  9. Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study.

    The oncologist · July 1, 2025 · Randomized controlled trial · cited 1 times · open access

    PMID 40592718 · DOI 10.1093/oncolo/oyaf167 · Human clinical research

  10. Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2.

    Journal of cachexia, sarcopenia and muscle · February 1, 2025 · Randomized controlled trial · cited 22 times · open access

    PMID 39992021 · DOI 10.1002/jcsm.13732 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.

    The Lancet. Oncology · February 20, 2016 · Randomized controlled trial · cited 640 times · open access

    PMID 26906526 · DOI 10.1016/s1470-2045(15)00558-6 · Human clinical research

  2. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).

    Cancer · December 4, 2017 · Randomized controlled trial · cited 240 times · open access

    PMID 29205286 · DOI 10.1002/cncr.31128 · Human clinical research

  3. Cancer Cachexia: Its Mechanism and Clinical Significance.

    International journal of molecular sciences · August 6, 2021 · Review · cited 234 times · open access

    PMID 34445197 · DOI 10.3390/ijms22168491 · Reviews and meta-analyses

  4. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.

    The Lancet. Oncology · December 16, 2014 · Randomized controlled trial · cited 218 times

    PMID 25524795 · DOI 10.1016/s1470-2045(14)71154-4 · Human clinical research

  5. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.

    Annals of oncology : official journal of the European Society for Medical Oncology · August 1, 2017 · Other clinical trial · cited 179 times · open access

    PMID 28472437 · DOI 10.1093/annonc/mdx192 · Human clinical research

Latest publications

  1. Predictors of anamorelin discontinuation in patients with cancer-associated cachexia undergoing chemotherapy: A retrospective observational study.

    International journal of clinical pharmacology and therapeutics · November 1, 2026 · Observational human study · cited 0 times

    PMID 42596744 · DOI 10.5414/cp204974 · Human clinical research

  2. Predictors of early discontinuation and therapeutic response to anamorelin in patients with cancer cachexia: A retrospective study.

    International journal of clinical pharmacology and therapeutics · October 1, 2026 · Observational human study · cited 0 times

    PMID 42544527 · DOI 10.5414/cp204997 · Human clinical research

  3. Exploring Inhibitory Impacts of Anamorelin on Colorectal Cancer Proliferation via Regulation of Transketolase.

    Current medicinal chemistry · August 22, 2026 · In vitro study · cited 0 times

    PMID 42693844 · DOI 10.2174/0109298673450549260810115103 · In vitro studies

  4. Predictors of 12-Week Anamorelin Treatment Continuation in Gastrointestinal Cancer Cachexia: A Single-Center, Retrospective Study.

    Nutrition and cancer · August 11, 2026 · Observational human study · cited 0 times

    PMID 42578447 · DOI 10.1080/01635581.2026.2713785 · Human clinical research

  5. A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA).

    Journal of cachexia, sarcopenia and muscle · August 1, 2026 · Observational human study · cited 0 times · open access

    PMID 42411631 · DOI 10.1002/jcsm.70340 · Human clinical research

  6. Gamma-glutamyl Transferase and Triglycerides Associated with an Early Food Intake Response to Anamorelin in Gastrointestinal Cancer Cachexia.

    Internal medicine (Tokyo, Japan) · July 25, 2026 · Observational human study · cited 0 times · open access

    PMID 42528246 · DOI 10.2169/internalmedicine.7787-26 · Human clinical research

  7. Trends in the Use of Anamorelin Hydrochloride for Cancer Cachexia: Examining the Timing of Anamorelin Initiation.

    Annals of nutrition & metabolism · June 26, 2026 · Observational human study · cited 0 times · open access

    PMID 42360910 · DOI 10.1159/000553255 · Human clinical research

  8. Association between anamorelin therapy and renal function in patients with cancer cachexia: a propensity score-matched retrospective study.

    European journal of clinical pharmacology · June 16, 2026 · Observational human study · cited 0 times

    PMID 42298206 · DOI 10.1007/s00228-026-04110-x · Human clinical research

  9. Cost-Effectiveness Analysis of Anamorelin and Olanzapine for Cancer Cachexia in Non-Small Cell Lung Cancer Patients in Japan.

    Value in health regional issues · June 4, 2026 · Computational study · cited 0 times · open access

    PMID 42240544 · DOI 10.1016/j.vhri.2026.101653 · Computational studies

  10. Three-Week Monitoring After Anamorelin Initiation in Unresectable or Recurrent Pancreatic Cancer: Dietary Intake Category, Observed Body Weight, and Prognostic Nutritional Index.

    Journal of palliative medicine · June 3, 2026 · Observational human study · cited 0 times

    PMID 42237597 · DOI 10.1177/10966218261457190 · Human clinical research

Browse all 146 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Adlumiz; Anamorelin; ONO-7643; RC-1291

((TITLE_ABS:"Adlumiz" OR CHEM:"Adlumiz") OR (TITLE_ABS:"Anamorelin" OR CHEM:"Anamorelin") OR (TITLE_ABS:"ONO-7643" OR CHEM:"ONO-7643" OR TITLE_ABS:"ONO7643" OR CHEM:"ONO7643") OR (TITLE_ABS:"RC-1291" OR CHEM:"RC-1291" OR TITLE_ABS:"RC1291" OR CHEM:"RC1291")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Anamorelin research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/anamorelin